Brain-specific gene expression changes in FXS mouse model after Sulindac or Ibudilast treatment

Fragile X syndrome (FXS) is a neurodevelopment disorder brought about by silencing of the Fragile X messenger ribonucleoprotein 1 (FMR1) gene. FXS is characterised by intellectual disability and symptoms akin to autism spectrum disorder (ASD) in both patients and FXS mouse models. Previous studies have shown that Ibudilast and Sulindac can reverse several phenotypic traits in an FXS mouse model. To delve deeper into the mechanisms underlying this reversal, we conducted RNA-Seq experiments to identify brain-specific gene expression changes induced by drug treatment. This approach offers insights into the pathways driving the efficacy of these treatments in the FXS mouse model.